Mapatumumab
Modify Date: 2024-02-01 19:11:10
Mapatumumab structure
|
Common Name | Mapatumumab | ||
|---|---|---|---|---|
| CAS Number | 658052-09-6 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of MapatumumabMapatumumab (HGS-ETR1) is a fully human IgG1 agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). Mapatumumab can be used for the research of cancer[1]. |
| Name | Mapatumumab |
|---|
| Description | Mapatumumab (HGS-ETR1) is a fully human IgG1 agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). Mapatumumab can be used for the research of cancer[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Mapatumumab (0.01-100 μg/mL; 4 h) shows no growth inhibition to Pediatric Preclinical Testing Program (PPTP) cell lines[1]. Mapatumumab (1-100 ng/mL; 24 h) shows significant potentiation of cytotoxicity and synergy when combined with (epirubicin) EPI for bladder cancer cells[2]. Mapatumumab (100 ng/mL; 12 h) induces significant cell apoptosis of T24, 253J and J82 cells with the combination of EPI (1 µg/mL)[2]. Mapatumumab (100 ng/mL; 6-24 h) significantly activates caspase-8, -9 and -3 with the combination of EPI (1 µg/mL)[2]. |
| In Vivo | Mapatumumab (10 mg/kg; i.p. for three times) controls tumor growth when combined with irradiation[3]. Animal Model: Colo205-xenograft–bearing NMRI (nu/nu) nude mice[3] Dosage: 10 mg/kg Administration: Intraperitoneal injection; 10 mg/kg; on days 1, 4, and 8 Result: Showed no significant differences when used alone, but when combined with irradiation (5×3 Gy, d1–5) showed a pronounced tumor regrowth-delay. |
| References |
| No Any Chemical & Physical Properties |